Anand Varadan joins Chiasma as Chief Commercial Officer

Takes responsibility for commercial activities in the US and Europe around launch of oral octreotide capsules

Chiasma, a US late-stage biopharmaceutical company developing octreotide capsules for the orphan condition acromegaly, has hired Anand Varadan as Chief Commercial Officer. He takes the role on 17 August.

Varadan brings more than 20 years of commercial experience to Newton, MA-based Chiasma and will take responsibility for all commercial activities in the US and Europe around the company's launch of oral octreotide capsules for acromegaly. In June, Chiasma submitted a New Drug Application (NDA) to the US FDA for octreotide capsules for this indication.

Varadan joins Chiasma from Amgen, where he was Vice President of Marketing for the US Inflammation and Nephrology Business Unit. Prior to Amgen, he held brand manager positions at Procter and Gamble, where he led the US pre-launch for Actonel for osteoporosis and the brand team for Asacol for ulcerative colitis.

You may also like

Manufacturing

Lonza to manufacture oral somatostatin analogue MYCAPSSA drug candidate in the UK

The Swiss CDMO has signed an advance commercial supply agreement with Chiasma, the US-based biopharma company
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Subscribe now